Seattle Genetics (SGEN) will receive undisclosed milestone payments from Genentech after the...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

Seattle Genetics (SGEN) will receive undisclosed milestone payments from Genentech after the Roche unit advanced into Phase II trials two antibody-drug conjugates (ADC) that use SGEN's technology. The studies will evaluate the performance of the ADCs with Rituxan, which Genentech markets, in treating non-Hodgkin lymphoma and B-cell lymphoma. (PR)